A nurse is caring for a patient with stage 4 chronic kidney disease (CKD) who has developed hyperphosphatemia. Which nursing intervention should be the priority?
1Educate the patient about dietary phosphorus restriction and phosphate binder administration✓ 정답
2Monitor for signs of hypocalcemia and tetany
3Increase fluid intake to promote phosphorus excretion
4Administer calcium supplements to counteract phosphorus elevation
해설
In stage 4 CKD with hyperphosphatemia, patient education on dietary phosphorus restriction and phosphate binder administration is the priority for long-term management and prevention of complications like bone disease and cardiovascular calcification. Other options address monitoring or acute interventions but do not provide sustainable management.
Core Nursing ExplanationKey Concept Analysis: This question assesses the priority nursing intervention for managing Hyperphosphatemia in a patient with Chronic Kidney Disease (CKD). The pathophysiology is central: as kidney function declines (Stage 4 CKD: GFR 15-29 mL/min), the kidneys cannot excrete excess phosphorus. This leads to elevated serum phosphorus levels, which binds with calcium, causing Hypocalcemia. The body compensates by increasing Parathyroid hormone (PTH) secretion, leading to Secondary hyperparathyroidism and Renal osteodystrophy. The priority is a long-term, preventive strategy that the patient can implement daily.
Answer Rationale: Key Point! The correct answer is Educate the patient about dietary phosphorus restriction and phosphate binder administration. This is the cornerstone of managing hyperphosphatemia in CKD. Education empowers the patient for self-management, which is critical for a chronic condition. Dietary restriction limits phosphorus intake, and phosphate binders (like calcium acetate, sevelamer, or lanthanum) bind dietary phosphorus in the gut, preventing its absorption. This directly addresses the root cause and prevents long-term complications like bone disease and vascular calcification.
Distractor Analysis:
Watch out for confusion! Option ②, "Monitor for signs of hypocalcemia and tetany," is an important assessment action but is not the priority intervention. Monitoring is reactive; education and treatment are proactive. Tetany is a sign of severe hypocalcemia, which is a consequence of hyperphosphatemia. Preventing the high phosphorus is more fundamental than monitoring for its effects.
Watch out for confusion! Option ③, "Increase fluid intake to promote phosphorus excretion," is contraindicated in advanced CKD. Patients with Stage 4 CKD often have fluid restrictions to prevent volume overload, hypertension, and heart failure. The kidneys are too damaged to excrete excess fluid or phosphorus effectively through increased urine output.
Watch out for confusion! Option ④, "Administer calcium supplements to counteract phosphorus elevation," is incorrect and potentially dangerous. While calcium-based phosphate binders (like calcium acetate) are used to bind phosphorus, administering plain calcium supplements without the intent of binding food can worsen Hypercalcemia and accelerate vascular and soft tissue calcification. The goal is to lower phosphorus, not simply to raise calcium.
Related Concepts: This integrates Chronic Disease Management, Patient Education, and understanding of the Calcium-Phosphorus-PTH axis. In CKD, managing electrolytes is a balancing act to prevent renal bone disease and cardiovascular morbidity.
Concept Summary
Concept
Key Point
Hyperphosphatemia in CKD
Result of decreased glomerular filtration. Leads to hypocalcemia and secondary hyperparathyroidism.
Phosphate Binders
Medications (calcium-based, sevelamer, lanthanum) taken with meals to bind dietary phosphorus.
Bone disease from CKD due to mineral and hormone imbalances (high P, low Ca, high PTH).
Side-by-Side Comparison!
Intervention
Rationale in CKD
Why It's Not the Priority Here
Patient Education (Correct)
Empowers for lifelong management. Addresses cause (intake/absorption). Prevents complications.
N/A - This is the priority.
Monitor for Hypocalcemia
Important for safety to detect complications of hyperphosphatemia.
Reactive, not proactive. Doesn't treat the underlying problem.
Increase Fluid Intake
Normally helps excrete solutes.
Contraindicated in advanced CKD due to risk of fluid overload. Kidneys can't respond.
Administer Calcium Supplements
May correct low serum calcium.
Can cause hypercalcemia and metastatic calcification. Does not lower phosphorus.
Anatomy, Physiology & Pharmacology Points
Physiology: Healthy kidneys excrete ~90% of dietary phosphorus. The Calcium-Phosphorus Product (Ca x P) should be < 55 mg²/dL² to prevent calcification.
Pharmacology: Phosphate binders must be taken with meals or immediately after to bind phosphorus in food. Calcium-based binders (e.g., calcium acetate) are contraindicated if serum calcium is high or if patient has vascular calcification.
Lab Values: Normal Serum Phosphorus: 2.5-4.5 mg/dL. In CKD, goal is often < 5.5 mg/dL. Stage 4 CKD GFR: 15-29 mL/min.
Memory Tips
Acronym: For CKD mineral management, think B.E.D.: Binders with meals, Educate on diet, Don't give extra fluids or calcium supplements freely.
Association: High Phosphorus "Pulls" calcium out of the blood (causing low Ca) and into soft tissues (causing calcification).
High-Frequency NCLEX Topics
NCLEX loves to test priority-setting and patient education in chronic conditions. CKD and electrolyte imbalances are core topics. Remember: Teaching is often a priority for chronic, manageable conditions. Also, know the contraindications for fluid administration in renal and heart failure patients.
Watch Out for Question Variations!
Instead of asking for the priority intervention, it might ask: "The nurse is evaluating the effectiveness of teaching. Which statement by the patient indicates understanding?" (Correct answer would be about taking binders with meals or listing low-phosphorus foods).
The scenario could shift to a patient experiencing Tetany. The question might then ask for the immediate nursing action (which would be airway/safety and administering IV calcium gluconate per protocol), contrasting acute vs. chronic management.
Nursing Clinical Practice GuideClinical Scenario: Mr. Johnson, 68, with Stage 4 CKD (GFR 22 mL/min) due to long-standing diabetes and hypertension. His latest labs show: Phosphorus 6.8 mg/dL, Calcium 8.1 mg/dL, and elevated PTH. He reports occasional bone pain and itching.
Nursing Intervention Strategy:
Assessment: Complete a dietary recall focusing on dairy, nuts, beans, dark colas, and processed foods. Assess understanding of his medications. Check for signs of hypocalcemia (Chvostek's sign, Trousseau's sign, paresthesias).
Nursing Diagnosis: Deficient Knowledge regarding dietary management and medication regimen for hyperphosphatemia.
Planning & Implementation:
Education Session: Use visual aids. Explain the link between high phosphorus, low calcium, bone disease, and itchy skin. Provide a printed list of "Foods to Choose" (fresh fruits/vegetables, white bread/rice) and "Foods to Limit/Avoid" (cheese, yogurt, nuts, beans, organ meats, cola).
Medication Management: Teach that phosphate binders (e.g., "Take your calcium acetate 2 pills with each meal") are not a substitute for diet but work with it. Emphasize timing—with food. Demonstrate with a pretend meal if needed.
Collaboration: Report lab findings to the nephrologist. Discuss potential need to adjust binder dose or switch to a non-calcium-based binder if calcium levels rise.
Evaluation: At follow-up, ask Mr. Johnson to teach back his diet plan and medication schedule. Review subsequent phosphorus and calcium lab values.
Patient Safety and Precautions:
Contraindication: Do not encourage liberal fluid intake. Adhere to prescribed fluid restrictions.
Medication Caution: Calcium-based binders can cause constipation. Advise on fiber intake (within renal diet limits) and stool softeners if needed. Monitor for hypercalcemia symptoms (nausea, vomiting, confusion, polyuria).
Key Monitoring: Track the calcium-phosphorus product. Routinely assess for signs of vascular calcification (decreased peripheral pulses, worsening hypertension).
Nursing Procedure & Medication FlowAdministering/Teaching About Phosphate Binders:
Verify: Check the specific binder (calcium acetate, sevelamer, lanthanum carbonate) and dose.
Timing is Critical: Instruct patient to take the medication with meals or snacks. The binder needs to mix with food in the stomach to be effective.
Do Not Crush or Chew some formulations (like sevelamer carbonate tablets) unless specified. Follow pharmacy instructions.
Space Other Medications: Binders can also bind other drugs (like thyroid medication, antibiotics). Advise taking other medications at least 1 hour before or 2-3 hours after the phosphate binder.
A Word from Your Senior Nurse
Managing CKD is a marathon, not a sprint. Your role as an educator is powerful—you're giving the patient the tools to slow their disease progression and improve their quality of life. When you see a lab value like high phosphorus, don't just think "abnormal." Think: "What is the patient eating? Do they understand their meds? What long-term damage can this cause?" That holistic, teaching-focused mindset is what makes an excellent nurse and is exactly what NCLEX wants to see. You're not just following orders; you're building a partnership for health.
Chronic Kidney Disease — Progressive loss of kidney function over months or years, categorized in stages based on Glomerular Filtration Rate (GFR).
Hyperphosphatemia — Abnormally high level of phosphate in the blood, a common complication in late-stage CKD due to decreased renal excretion.
Phosphate Binders — Medications (e.g., calcium acetate, sevelamer) that bind to dietary phosphorus in the gastrointestinal tract, preventing its absorption into the bloodstream.
Secondary Hyperparathyroidism — Overactivity of the parathyroid glands in response to low calcium levels, often caused by hyperphosphatemia in CKD, leading to bone resorption.
Renal Osteodystrophy — A bone mineral metabolism disorder occurring in CKD, resulting from imbalances in calcium, phosphorus, and parathyroid hormone (PTH).